ALK improves earnings guidance as sales grow across markets

7 November 2019

Denmark-based allergy specialist ALK-Abelló (ALKB: DC) reported that revenues had risen by 11% in local currencies as the company presented its third-quarter 2019 results.

Total revenue hit 739 million Danish kroner ($110 million), with growth in sales in all regions, including a 6% rise in Europe, a 17% jump in North America and an 80% rise in international markets.

Earnings before interest, taxes, depreciation and amortization (EBITDA) were 36 million Danish kroner, a rise of 50%, and ALK has improved its EBITDA guidance for the year to between 200 and 250 million Danish kroner, from the previous estimate of 150 to 250 million.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK